Clinical trials: Ascites
Portal Hypertension, Liver Diseases
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure.
- Conditions
- Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax
- Trial name
- NCT05765253
- Testing
- Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Argon Medical Devices
Malignant Pleural Effusion, Malignant Ascites
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
- Trial name
- NCT01327235
- Testing
- Endostar, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Congestive Heart Failure, Ascites
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
A 28-week, feasibility study to investigate the safety and efficiency of the Automatic Fluid Shunt in patients with chronic congestive heart failure, ascites and diuretic resistance.
- Trial name
- NCT00907673
- Testing
- Automatic Fluid Shunt System
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- NovaShunt AG
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Malignant Ascites Due to Epithelial Carcinoma
Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
This phase II single arm, open-label study investigate the safety of a second cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS…
- Trial name
- SECIMAS (NCT01065246)
- Testing
- catumaxomab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Neovii Biotech
Malignant Ascites
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
Treatment of malignant ascites with the alfapump offers a new treatment option for this patient group. So far, there is no systematic analysis of patients with this indication available in the literature.
- Trial name
- NCT03200106
- Testing
- Alfapump
- Where
- 3 sites in Germany, Switzerland and 1 more
- Volunteers
- 17 people
- Sponsor
- Sequana Medical N.V.
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Liver Cirrhosis
Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients
The objective of this study is to evaluate the correlation of the calculated portosystemic pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with the EchoTip® Insight™ and indirect portal vein…
- Trial name
- NCT04987034
- Testing
- EchoTip® Insight™
- Where
- 3 sites in Belgium, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Cook Research Incorporated
Cirrhosis, Ascites Hepatic
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
- Trial name
- NCT03107091
- Testing
- Terlipressin acetate continuous infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioVie Inc.
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.
- Trial name
- Normo~CAT (NCT00501566)
- Testing
- satavaptan (SR121463B)
- Where
- 12 sites in Argentina, Australia and 10 more
- Volunteers
- 148 people
- Sponsor
- Sanofi
Cirrhosis, Liver, Liver Fibrosis
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2).
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Trial name
- NCT05490888
- Testing
- PHIN-214 Subcutaneous injection
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- PharmaIN
Malignant Ascites
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles…
- Trial name
- SIM0388-101 (NCT07007988)
- Testing
- SIM0388
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cirrhotic Ascites
Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia
M0002, an orally active, selective non-peptidergic antagonist of the vasopressin V2 receptor inhibits vasopressin-induced water reabsorption from the kidney.
- Trial name
- NCT01179607
- Testing
- M0002
- Volunteers
- 15 people
- Sponsor
- Movetis
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Ascites Hepatic
A Study of OsrHSA in Adult Healthy Male and Female Volunteers
A Phase 1 randomized, double blinded, placebo-controlled single dose escalation study of OsrHSA in adult healthy male and female volunteers
- Trial name
- NCT04384523
- Testing
- OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Healthgen Biotechnology Corp.
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in the Prevention of Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone.
- Trial name
- SPA (NCT00501384)
- Testing
- satavaptan (SR121463B)
- Where
- 11 sites in Argentina, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- Sanofi
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Hepatic Ascites
A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites
This study was a Phase III multicenter, blinded, and positive active-controlled clinical study to evaluate the efficacy, safety, and immunogenicity of recombinant human albumin(rHA) injection for the treatment of hypoalbuminemia…
- Trial name
- NCT06911554
- Testing
- Recombinant Human Albumin Injection, Human Albumin
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Tonghua Anrate Biopharmaceutical Co., Ltd.